Clinical Trials
23 trialsGETUG-AFU 40
UNICANCER
Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC
Weill Medical College of Cornell University
ANCHORProstate
Centre hospitalier de l'Université de Montréal (CHUM)
METRO
Umeå University
STAMPEDE2
University College, London
FTT PET/CT in Metastatic Prostate Cancer
Abramson Cancer Center at Penn Medicine
TRIUMPH
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID)
Fudan University
ACTION
Weill Medical College of Cornell University
ROTOR
The Netherlands Cancer Institute
68Ga-P15-041 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Prostate Bone Metastasis
Peking Union Medical College Hospital
IMANOL
Spanish Oncology Genito-Urinary Group
BAseLine TEstosterone as a Prognostic and/or Predictive bioMARKer in mHSPC
University Hospital Virgen de las Nieves
CABASTY
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
PET/CT and WB MRI for Staging and Response in CRPC Patients Receiving Enzalutamide
The European Uro-Oncology Group
Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide
The European Uro-Oncology Group
iPROMET
Vall d'Hebron Institute of Oncology
Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer
University of Hawaii
A Multi-omics Study of Metastatic Prostate Cancer (MOSMPCA)
West China Hospital
Telaglenastat + Talazoparib In Prostate Cancer
Massachusetts General Hospital
Oligomet_DK
Herlev Hospital
uPAR PET/CT in Radium-223-dichloride Treatment of Patients With Metastatic Castration-resistant Prostate Cancer
Rigshospitalet, Denmark
Post-eRADicAte
Carolina Research Professionals, LLC